With pan-RAF drug from Takeda, Day One unveils its first pediatric brain cancer data. And the market loves it
Day One Biopharmaceuticals has gathered the first cut of Phase II data on its quest to reposition a Takeda drug as a treatment for pediatric cancer, and investors are evidently thrilled.
With an overall response rate of 64% among the first 25 patients who have a type of brain tumor called recurrent or progressive low-grade glioma (pLGG), Day One said late Sunday the results bode well for the rest of the FIREFLY-1 study, which features a registrational cohort out of three arms. That cohort is fully enrolled and expected to get to a readout in 2023.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 154,000+ biopharma pros reading Endpoints daily — and it's free.